GeneDx Begin Period Cash Flow from 2010 to 2024
| WGS Stock | 78.39 1.04 1.31% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 137.4 M | Current Value 170.3 M | Quarterly Volatility 112 M |
Check GeneDx Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneDx Holdings' main balance sheet or income statement drivers, such as Net Interest Income of 1.2 M, Interest Income of 3.1 M or Depreciation And Amortization of 30.9 M, as well as many indicators such as Price To Sales Ratio of 0.31, Dividend Yield of 0.0 or PTB Ratio of 0.52. GeneDx financial statements analysis is a perfect complement when working with GeneDx Holdings Valuation or Volatility modules.
GeneDx | Begin Period Cash Flow |
Latest GeneDx Holdings' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of GeneDx Holdings Corp over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. GeneDx Holdings' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
GeneDx Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 63,660,101 | |
| Geometric Mean | 6,137,992 | |
| Coefficient Of Variation | 175.95 | |
| Mean Deviation | 83,309,468 | |
| Median | 1,178,000 | |
| Standard Deviation | 112,012,764 | |
| Sample Variance | 12546.9T | |
| Range | 400.3M | |
| R-Value | 0.69 | |
| Mean Square Error | 7142.3T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | 17,196,984 | |
| Total Sum of Squares | 175656T |
GeneDx Begin Period Cash Flow History
About GeneDx Holdings Financial Statements
GeneDx Holdings shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although GeneDx Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in GeneDx Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on GeneDx Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 137.4 M | 170.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.